Tirzepatide for Sleep Apnea: Who the Evidence Applies To

Obstructive sleep apnea (OSA) happens when the upper airway repeatedly narrows or closes during sleep, interrupting breathing. It can leave people exhausted during the day and is linked with heart and metabolic health risks. In December 2024, the US FDA approved Zepbound (tirzepatide) to treat moderate-to-severe OSA in adults with obesity, alongside reduced-calorie eating and increased physical activity. That was a meaningful step, because the trials behind it measured sleep-apnea outcomes, not just weight.

What did SURMOUNT-OSA study?

SURMOUNT-OSA was actually two 52-week randomized, placebo-controlled trials in adults with obesity and moderate-to-severe OSA who did not have type 2 diabetes (469 people in total):

• Trial 1: people not using positive airway pressure (PAP), such as CPAP.
• Trial 2: people already using PAP therapy.

Participants received the highest dose they could tolerate (10 mg or 15 mg weekly) or placebo. The main measure was the apnea-hypopnea index (AHI), the number of times per hour breathing stops or becomes shallow during sleep.

What did it find?

At the start, participants averaged about 50 events per hour, which is in the severe range. After 52 weeks:

• In trial 1, AHI fell by about 25 events per hour with tirzepatide versus about 5 with placebo.
• In trial 2, AHI fell by about 29 events per hour with tirzepatide versus about 6 with placebo.

People on tirzepatide also lost more weight and had improvements in oxygen-related measures, blood pressure and patient-reported sleep impairment. The most common side effects were gastrointestinal and mostly mild to moderate. The trials were funded by Eli Lilly, the manufacturer.

These results apply to the studied population and treatment period. They don't tell us much about people without obesity, people with type 2 diabetes (who weren't included), or everyone who snores.

Does this mean weight-loss medicine replaces CPAP?

Not automatically. Please don't stop PAP or any other OSA treatment without talking to your care team. The right mix of PAP, medication, weight management and other options depends on your diagnosis and situation. A sleep specialist can assess whether symptoms have changed and whether repeat sleep testing makes sense. Snoring alone can't diagnose sleep apnea, and tiredness has many possible causes.

Why the exact product matters

In the United States, tirzepatide is sold under two brand names with different labels. As of October 2026, the OSA indication belongs to Zepbound. Mounjaro, which also contains tirzepatide, is labeled for type 2 diabetes and, since August 2026, for reducing cardiovascular risk in some adults with type 2 diabetes, but not for OSA. Names and approvals differ by country, so it's worth checking the label where you live. Our Mounjaro vs Ozempic guide explains more about how brand names and labels line up.

When to seek a sleep assessment

Loud habitual snoring, someone noticing you stop breathing, waking up gasping or choking, morning headaches or strong daytime sleepiness (especially dozing off while driving) are all good reasons to talk with a clinician about OSA. If you already have diagnosed OSA, ask how weight changes should affect your monitoring and treatment. For sleep questions beyond apnea, see GLP-1s and sleep.

The encouraging news is that randomized-trial evidence supports tirzepatide for a specific OSA population. The safe interpretation is that it adds an option, not that sleep apnea can be self-diagnosed or that existing care should stop without review.